House of Lords Business
Show full summary

Lord Mendelsohn to ask His Majesty's Government, further to the publication of the RAPID C-19 Oversight Group report on 6 October, whether the Antivirals and Therapeutics Taskforce has determined the nature and threshold of evidence required for a prophylactic monoclonal antibody treatment to be made available via interim clinical policy before an appraisal by the National Institute for Health and Care Excellence.  HL4103

Question HL4103: tabled on 7 December 2022 and due for answer by 21 December 2022

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Mendelsohn to ask His Majesty's Government, further to the publication of the RAPID C-19 Oversight Group report on 6 October, whether the Antivirals and Therapeutics Taskforce has determined the nature and threshold of evidence required for a prophylactic monoclonal antibody treatment to be made available via interim clinical policy before an appraisal by the National Institute for Health and Care Excellence.  HL4103
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Mendelsohn
Labour
Life peer